Cardiovascular & Thoracic Surgery News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

CAR T-Cell Therapy Showing Promise with Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center continues its drive toward a future that may involve innovative CAR T-cell therapy as part of standard-of-care treatment for malignant pleural mesothelioma. The latest step was a clinical trial exploring a first-in-human, intrapleural-administered CAR T-cell therapy used in combination with pembrolizumab, a well-known immunotherapy drug also known by the brand name Keytruda. Results were impressive, including a 23.9-month median overall survival and an 83% one-year survival rate for patients. Cancer Discovery published the single-center study results July 15. “There is more...
Source: Asbestos and Mesothelioma News - July 22, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news

Survival after cardiac arrest - Freiburg cardiovascular surgeons develop new technique
(University of Freiburg) German researchers have developed a novel therapeutic approach for resuscitation after cardiac arrest that allows much higher success rates than before - often without neurological complications / Study in Nature Reviews Neuroscience summarizes decisive factors / New heart-lung machine " makes clinical implementation possible. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 22, 2021 Category: International Medicine & Public Health Source Type: news

RNA modification may protect against liver disease, explain liver fat differences between sexes
FINDINGSA chemical modification that occurs in some RNA molecules as they carry genetic instructions from DNA to cells ’ protein-making machinery may offer protection against non-alcoholic fatty liver, a condition that results from a build-up of fat in the liver and can lead to advanced liver disease, according to a new study by UCLA researchers.The study, conducted in mice, also suggests that this modification — known as m6A, in which a methyl group attaches to an RNA chain — may occurat a different ratein femalesthan it does inmales, potentially explaining why females tend to have higher fat content in the liver. T...
Source: UCLA Newsroom: Health Sciences - July 19, 2021 Category: Universities & Medical Training Source Type: news

Johnson & Johnson Innovation Announces Extension Of Innovation Partnering Office at Monash University In Collaboration With Victorian State Government To Accelerate The Life-Sciences Hub
MELBOURNE, Australia, July 15, 2021 -- Johnson & Johnson Innovation announced today the extension of the Johnson & Johnson Innovation Partnering Office at Monash University's Clayton Campus in Melbourne (JJIPO@Monash) in collaboration with the Victorian State Government.This joint initiative between Johnson & Johnson Innovation, the Victorian Government and Monash University will be extended for approximately two years through June 30, 2023. The agreement will allow JJIPO@Monash to continue connecting with the Victorian innovation ecosystem, nurturing and accelerating innovative research, new product developmen...
Source: Johnson and Johnson - July 15, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Blood Management for Cardiothoracic Surgery: Guidelines Update Blood Management for Cardiothoracic Surgery: Guidelines Update
The Society of Thoracic Surgeons ' document, created with multidisciplinary collaboration, includes 23 new or updated recommendations.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 7, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Deep learning plus CT helps predict abdominal surgery outcomes
A deep-learning model used with preoperative CT helps predict the complexit...Read more on AuntMinnie.comRelated Reading: Algorithm provides accurate segmentation of pancreas on CT CT, ultrasound provide chance for fatty liver disease screening AI abdominal fat analysis assesses cardiovascular risk AI can opportunistically screen for metabolic syndrome AI plus CT improves liver steatosis assessment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 7, 2021 Category: Radiology Source Type: news

Guideline Updated for Blood Management During Heart Surgery
WEDNESDAY, June 30, 2021 -- In a clinical practice guideline update, published online June 30 in the Annals of Thoracic Surgery, recommendations are presented for patient blood management during cardiothoracic surgery. In collaboration with the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2021 Category: Pharmaceuticals Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Bariatric Surgery Leads to Better CV Function in Pregnancy Bariatric Surgery Leads to Better CV Function in Pregnancy
The cardiovascular adaptation of pregnant women after bariatric surgery suggests better hemodynamic function through lower blood pressure, heart rate, and cardiac output, new data show.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 23, 2021 Category: Cardiology Tags: Ob/Gyn & Women ' s Health News Source Type: news

Bariatric Surgery's Cardiovascular Benefit Extends to 7 Years Bariatric Surgery's Cardiovascular Benefit Extends to 7 Years
Patients with obesity who had bariatric surgery had a lower risk of having a major adverse cardiovascular event (MACE) or dying from all causes during a median 7-year follow-up, compared with similar patients who did not undergo surgery.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 22, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Ethicon Expands Advanced Biopolar Energy Portfolio With Launch Of Enseal X1 Curved Jaw Tissue Sealer
CINCINNATI, OH – June 21, 2021 -- Ethicon*, part of the Johnson & Johnson Medical Devices Companies,** today announced the launch of the ENSEAL X1 Curved Jaw Tissue Sealer, a new advanced bipolar energy device that increases procedural efficiency[1] and provided stronger sealing[2] and better access to more tissue than LigaSure™ Maryland.[3] The device is indicated for colorectal, gynecological, bariatric surgery and thoracic procedures. The ENSEAL X1 Curved Jaw is the first of several new advanced laparoscopic bipolar devices the company plans to launch in the coming months as it expands its extensive energy portf...
Source: Johnson and Johnson - June 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Clinical Trial Shows Benefits of Vinorelbine for Mesothelioma
Mesothelioma specialist Dr. Dean Fennell has strongly endorsed the use of vinorelbine as a second-line treatment for patients with relapsed disease. He was the lead investigator in a recent phase II clinical trial studying the efficacy of vinorelbine for patients whose pleural mesothelioma cancer had progressed after traditional platinum-based chemotherapy. Fennell, who is chair of thoracic and medical oncology at University of Leicester and University Hospitals in the United Kingdom, has based his belief on the multicenter trial involving 154 mesothelioma patients with relapsed disease. “Doctors should now feel...
Source: Asbestos and Mesothelioma News - June 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Women Present With More Advanced Acute Aortic Dissection
MONDAY, June 14, 2021 -- Women with acute aortic dissection are older and have more advanced disease at presentation than men, according to a study published online June 1 in The Annals of Thoracic Surgery. Lauren V. Huckaby, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2021 Category: Pharmaceuticals Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of re...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news